Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
IGHV5-51 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV5-51 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV5-51 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV7-81 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV7-81 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV7-81 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV4-39 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV4-39 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV4-39 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV4-61 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV4-61 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV4-61 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV4-4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV4-4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV4-4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV4-59 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV4-59 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV4-59 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV4-38-2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV4-38-2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV4-38-2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV4-30-2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV4-30-2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV4-30-2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV4-34 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV4-34 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV4-34 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV4-31 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV4-31 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV4-31 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV4-30-4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV4-30-4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV4-30-4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGHV4-28 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGHV4-28 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGHV4-28 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →